SUBSCRIBE
SUBSCRIBE
News   Drug Development

OrthoLogic Corporation Announces Completion of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring

August 15, 2008 | 
1 min read

TEMPE, Ariz., Aug. 14, 2008 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the completion of dosing for its second AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring. Patient follow-up is ongoing.

Clinical research Phase I
MORE ON THIS TOPIC
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Weight loss
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Gothenburg, Sweden – April 17, 2020: AstraZeneca in Gothenburg is one of three strategic global R&D centres in medicine. A big sign with the company logotype just outside the entrance.
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
February 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky